Spots Global Cancer Trial Database for ptcl
Every month we try and update this database with for ptcl cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | NCT04328844 | Solid Tumor, Ad... Non-Hodgkin Lym... NSCLC Myelofibrosis Uveal Melanoma | IOA-244 Avelumab Inject... Pemetrexed Cisplatin Ruxolitinib | 18 Years - | iOnctura | |
| A Safety Study of SGN-35T in Adults With Advanced Cancers | NCT06120504 | Lymphoma, T-Cel... Hodgkin Disease Lymphoma, T-Cel... Lymphoma, Large... Lymphoma, Large... Lymphoma, Non-H... | SGN-35T | 18 Years - | Seagen Inc. | |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | NCT02440685 | Lymphoma, Large... Lymphoma, Mantl... Lymphoma, Folli... Cancer Neoplasm Tumor Lymphoma, Malig... Lymphoma, B-cel... Lymphoma, Non-H... B-Cell Chronic ... B-Cell Leukemia... B-Lymphocytic L... Chronic Lymphoc... Leukemia, Lymph... Leukemia, Lymph... Myelofibrosis Chronic Idiopat... Idiopathic Myel... Lymphoma, T Cel... Peripheral T-Ce... T-Cell Lymphoma... | ASN002 Dose Esc... ASN002 RD | 18 Years - | Asana BioSciences | |
| A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma | NCT03952078 | T-cell Lymphoma | CPI-818 | 18 Years - | Corvus Pharmaceuticals, Inc. | |
| Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL) | NCT00972842 | Peripheral T-Ce... | Vorinostat, Len... | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | NCT04328844 | Solid Tumor, Ad... Non-Hodgkin Lym... NSCLC Myelofibrosis Uveal Melanoma | IOA-244 Avelumab Inject... Pemetrexed Cisplatin Ruxolitinib | 18 Years - | iOnctura | |
| Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL | NCT00355472 | Adult T-Cell Le... Adult Periphera... | KW-0761 | 20 Years - 69 Years | Kyowa Kirin Co., Ltd. | |
| A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | NCT01716806 | Hodgkin Disease Peripheral T Ce... | brentuximab ved... bendamustine dacarbazine nivolumab | 18 Years - | Seagen Inc. | |
| Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) | NCT01839097 | Peripheral T-ce... | Belinostat CHOP | 18 Years - | Acrotech Biopharma Inc. | |
| Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma | NCT00865969 | Peripheral T-ce... | Belinostat | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma | NCT01139359 | Lymphoma | darinaparsin CHOP | 18 Years - | Alaunos Therapeutics | |
| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL | NCT05138458 | Lymphoma, T-Cel... Lymphoma, T-Cel... Mycosis Fungoid... Adoptive Cellul... Cell Therapy | MT-101 MT-101 + Condit... | 18 Years - | Myeloid Therapeutics | |
| A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) | NCT02594267 | Peripheral T-Ce... | Pralatrexate In... | 18 Years - | Acrotech Biopharma Inc. | |
| Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients | NCT02809573 | Peripheral T-ce... | Chidamide cyclophosphamid... adriacin vincristine prednisone | 18 Years - 65 Years | Chipscreen Biosciences, Ltd. | |
| Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma | NCT05079282 | Relapsed or Ref... | ONO-4685 | 18 Years - | Ono Pharmaceutical Co. Ltd | |
| Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma | NCT01139359 | Lymphoma | darinaparsin CHOP | 18 Years - | Alaunos Therapeutics | |
| Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL | NCT03240211 | PTCL CTCL | Pembrolizumab Pralatrexate Decitabine | 18 Years - 90 Years | University of Virginia | |
| A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas | NCT00274651 | Cutaneous T-Cel... Peripheral T-Ce... Non-Hodgkin's L... | belinostat | 18 Years - | Valerio Therapeutics | |
| Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients | NCT01036399 | Peripheral T-ce... | Lenalidomide | 18 Years - | University of Bologna | |
| SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma | NCT00787527 | Lymphoma | Zolinza (vorino... Cyclophosphamid... Doxorubicin Vincristine Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
| Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | NCT03601819 | Lymphoma, T-Cel... Lymphoma, T-Cel... Chronic Lymphoc... Lymphoprolifera... Waldenstrom Mac... Lymphoplasmacyt... Mantle Cell Lym... | Pacritinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | NCT02142530 | Non-Hodgkin Lym... Diffuse Large B... Mantle Cell Lym... Follicular Lymp... Peripheral T-ce... | Carfilzomib Belinostat | 18 Years - | Massachusetts General Hospital | |
| Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | NCT02503423 | Solid Tumors Lymphoma | ASTX660 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma | NCT00888927 | Peripheral T-Ce... | KW-0761 | 18 Years - | Kyowa Kirin Co., Ltd. | |
| AFM13 in Relapsed/Refractory Cutaneous Lymphomas | NCT03192202 | Lymphoma, T-Cel... | AFM13 | 18 Years - | Columbia University | |
| A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma | NCT04705090 | PTCL | YY-20394 treatm... | 18 Years - | Shanghai YingLi Pharmaceutical Co. Ltd. | |
| Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas | NCT02223208 | Peripheral T-ce... PTCL-NOS Angioimmunoblas... ALK- Anaplastic... Nodal Periphera... | Ro-CHOEP-21 (PH... Ro-CHOEP-21 (PH... | 18 Years - 65 Years | Fondazione Italiana Linfomi - ETS | |
| A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma | NCT01169298 | Adult T-cell Le... Peripheral T-ce... | Lenalidomide | 20 Years - | Celgene | |
| A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma | NCT04705090 | PTCL | YY-20394 treatm... | 18 Years - | Shanghai YingLi Pharmaceutical Co. Ltd. | |
| Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | NCT03786926 | Lymphoma | HMPL-689 | 18 Years - | Hutchmed | |
| Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma | NCT02567656 | Lymphoma, T-Cel... Lymphoma, T-Cel... | RP6530 | 18 Years - | Rhizen Pharmaceuticals SA | |
| A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) | NCT02594267 | Peripheral T-Ce... | Pralatrexate In... | 18 Years - | Acrotech Biopharma Inc. | |
| Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL | NCT03355768 | Lymphoma, T-Cel... | Romidepsin Pralatrexate | 18 Years - 90 Years | Columbia University | |
| Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | NCT02142530 | Non-Hodgkin Lym... Diffuse Large B... Mantle Cell Lym... Follicular Lymp... Peripheral T-ce... | Carfilzomib Belinostat | 18 Years - | Massachusetts General Hospital | |
| Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort | NCT03900442 | Advanced Cancer PTCL | PTX-100 | 18 Years - | Prescient Therapeutics, Ltd. | |
| A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) | NCT02594267 | Peripheral T-Ce... | Pralatrexate In... | 18 Years - | Acrotech Biopharma Inc. | |
| Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL) | NCT00972842 | Peripheral T-Ce... | Vorinostat, Len... | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Lenalidomide in Combination With CHOP in Patients With Untreated PTCL | NCT04423926 | PTCL, NOS AITL ALK- ALCL Phase III-IV AL... EATL | Lenalidomide Cyclophosphamid... Doxorubicin Vincristine Prednisolone | 18 Years - 70 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients | NCT01036399 | Peripheral T-ce... | Lenalidomide | 18 Years - | University of Bologna | |
| Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 | NCT01226472 | Peripheral T-ce... Cutaneous T-cel... | KW-0761 | 18 Years - | Kyowa Kirin Co., Ltd. | |
| Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma | NCT02314247 | Peripheral T-ce... Cutaneous T-cel... | Selinexor | 18 Years - | Karyopharm Therapeutics Inc | |
| Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | NCT01796002 | Peripheral T-ce... | Romidepsin + CH... CHOP | 18 Years - 80 Years | The Lymphoma Academic Research Organisation | |
| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL | NCT05138458 | Lymphoma, T-Cel... Lymphoma, T-Cel... Mycosis Fungoid... Adoptive Cellul... Cell Therapy | MT-101 MT-101 + Condit... | 18 Years - | Myeloid Therapeutics | |
| A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | NCT01716806 | Hodgkin Disease Peripheral T Ce... | brentuximab ved... bendamustine dacarbazine nivolumab | 18 Years - | Seagen Inc. | |
| A Safety Study of SGN-35T in Adults With Advanced Cancers | NCT06120504 | Lymphoma, T-Cel... Hodgkin Disease Lymphoma, T-Cel... Lymphoma, Large... Lymphoma, Large... Lymphoma, Non-H... | SGN-35T | 18 Years - | Seagen Inc. | |
| A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma | NCT04470141 | Peripheral T Ce... | SHC014748M trea... | 18 Years - | Nanjing Sanhome Pharmaceutical, Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
